2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1663

Influence of Age and Renal Impairment on Pharmacokinetics of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor
Abstract Number: 1664

Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.
Abstract Number: 1665

Treatment Patterns in Rheumatoid Arthritis after Methotrexate: Data from a Rheumatoid Arthritis Cohort
Abstract Number: 1666

Mitochondrial Haplogroups in Patients with Rheumatoid Arthritis with Respect to Biological Treatment
Abstract Number: 1667

Clinical Parameters and B Cell Subsets As Biomarkers of Response to Tocilizumab in Rheumatoid Arthritis
Abstract Number: 1668

Patterns of Relapse in the Rheumatoid Arthritis Cohort Treated with Rituximab at University College London
Abstract Number: 1669

Serum Survivin Predicts Responses to Treatment in Active Rheumatoid Arthritis
Abstract Number: 1670

Rapidity of Therapeutic Response of Biologics Compared to Methotrexate Monotherapy in Early RA: A Network Meta-Analysis
Abstract Number: 1671

Discovery of PRN1008, a Novel, Reversible Covalent BTK Inhibitor in Clinical Development for Rheumatoid Arthritis
Abstract Number: 1672

One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Abstract Number: 1673

The Transcription Factor Nuclear Protein Transcriptional Regulator 1 May Contribute to Increased Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis
Abstract Number: 1674

Predictive Factors of Persistence in Therapy with Abatacept in Patients with Rheumatoid Arthritis
Abstract Number: 1675

Efficacy and Safety of Switched CT-P10 from Innovator Rituximab Compared to Those of Maintained CT-P10 in Patients with Rheumatoid Arthritis up to 56 Weeks
Abstract Number: 1676

Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update
Abstract Number: 1677

Disease-Regulated Expression of Anti-Inflammatory Interleukin-10 for the Treatment of Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].